limit sampl model doxorubicin pharmacokinet doxorubicin use antineoplast studi date area concentration-tim curv auc toxic respons limit sampl model feasibl method auc pharmacodynam studi data previou studi doxorubicin pharmacokinet patient sarcoma patient breast cancer unknown primari former train data set patient test datum set patient latter patient second test data set model stepwis multipl regress train data set auc nanogram hour millilit dose/ concentr hour bolu dose model test data set test data set mean predict error mpe root mean squar error rmse second test data set mpe rmse addit model simul time point total auc daili schedul auc nanogram hour millilit dose/ third dose auc doxorubicin bolu administr plasma concentr 